Akarna Therapeutics Ltd. announced that it has been acquired by Allergan plc. Allergan obtains rights to AKN-083, Akarna’s lead product candidate for the potential treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases.
The outlook remains bright due to a favorable regulatory arena, support for biopharma-friendly legislation and development incentives, expanding scientific opportunities in key therapeutic areas such as immuno-oncology, and big pharma’s continued push to obtain innovation.
In mid-May, pharma giant Pfizer agreed to buy Anacor Pharmaceuticals for a total transaction value, net of cash, of $5.2 billion. Anacor is a biopharmaceutical company concentrated on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform.
The Biotechnology Industry Organization released a report titled: Emerging Therapeutic Company Investment and Deal Trends. BIO Industry Analysis says more than 90 percent of the biopharma industry is composed of small, emerging companies. According to BIO President Jim Greenwood and E. Cartier Esham, Ph.D., executive VP of BIO’s Emerging Companies Section, it is important for the trade association to better understand early-stage investor and deal-making trends in order to determine where scientific or policy issues may be affecting the ability to maintain a robust pipeline of innovative medicines.
Based on the closing of IMS Health and Quintiles common stock prices on May 2, 2016, the equity market capitalization of the joined companies is more than $17.6 billion and the enterprise value is more than $23 billion.
Gains full-rights to Padlock’s Protein/Peptidyl Arginine Deiminase (PAD) inhibitor discovery program Expands Bristol-Myers Squibb’s immunoscience pipeline with potentially transformational approach to treating rheumatoid arthritis and other autoimmune diseases March […]
Newport Beach, CA — March 15, 2016 Glutenase for in-vivo gluten degradation is a leading candidate for celiac disease ImmunogenX™, a biopharmaceutical company focused on the diagnosis and treatment […]
Addition of Biologic KRYSTEXXA® (pegloticase) Expands and Diversifies Horizon’s Orphan Business; Leverages Rheumatology Expertise and Infrastructure; Transaction Is Expected to Be Immediately Accretive to Adjusted EBITDA in 2016; Conference Call […]
The digital HCP engagement provider Physicians Interactive announced two major strategic moves in the past two months, acquiring the HCP content platform Univadis from Merck in October and then rebranding […]
Authoritative Medical Content Platform Combined with Deep Digital Expertise Offers Greater Opportunities to Engage Healthcare Professionals and Improve Outcomes READING, Mass., Oct. 21, 2015 /PRNewswire/ — Physicians Interactive® (PI) […]